key: cord-0883786-bbcfpt6z
authors: Finazzi, Tobias; Papachristofilou, Alexandros; Siegemund, Martin
title: Separating evidence from opinion – In regards to [XXX] et al.
date: 2021-04-29
journal: Int J Radiat Oncol Biol Phys
DOI: 10.1016/j.ijrobp.2021.04.026
sha: 061e40071202bdfa7de12c3fd47c41d0bb33a2d1
doc_id: 883786
cord_uid: bbcfpt6z

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 

We thank [XXX-et-al] for their comments on our study of whole-lung low-dose radiation therapy (LDRT) for severe COVID-19 pneumonia [1] . In their letter, [XXX-et-al.] suggest that suboptimal dose and timing of LDRT may explain the negative outcome.

[ XXX-et-al.] cite "substantial evidence" showing that 1 Gy may be beyond the range of effective doses for COVID-19 patients. Unfortunately, they did not provide references that adequately support this statement. In addition, our patients did not receive the prescribed dose of 1 Gy to the whole lungs. Rather, as described in the manuscript, the lungs received antiinflammatory doses in the range of 0.5 -1.0 Gy, which appears adequate based on recent preclinical research [2, 3] .

It is essential to acknowledge the uncertainty surrounding the "ideal" LDRT dose. [XXX-etal.] cite the Iranian study, and declare that their concept "clearly explains why Ameri et al.

concluded that 0.5 Gy was more effective than 1.0 Gy". This was not a conclusion of the study's authors, who address important limitations in their paper [4] . We cannot exclude that a different outcome would have been observed in our study with use of a lower radiation dose.

However, such assumptions are speculative, if not disconnected from the clinical reality of these patients, in whom LDRT failed to produce any meaningful effect.

Our study focused on ventilated patients, for whom the presumed risk-benefit ratio of LDRT appeared most favorable. Although an earlier application could be more effective, the longterm risks may outweigh potential benefits in less critically ill patients. Moreover, the timing of immunomodulatory treatments is complex. RECOVERY showed large benefits of dexamethasone in ventilated patients, but only small improvements in patients on oxygen [5] .

Tocilizumab, an interleukin-6 receptor antibody, may further reduce mortality in these patients [6] . Even if LDRT were to improve on these results, it would likely require large-scale randomized trials to show a potential benefit.

Our trial was borne out of a clinical need, and we chose a randomized double-blind design to reduce any potential bias. The availability of prospective controls is the crucial difference between our study and earlier reports [4, 7, 8] , a difference which [XXX-et-al.] unfortunately did not consider as a source of discrepancy between results. Although vaccines now provide a light at the end of the COVID-19 tunnel, the discussion of anti-inflammatory LDRT will go on. We should continue to separate evidence from opinion, and work together to investigate what's best for our patients both during and after the COVID-19 pandemic.

Low-dose radiation therapy for severe COVID-19 pneumonia: a randomized doubleblind study

Low doses of radiation increase the immunosuppressive profile of lung macrophages during viral infection and pneumonia

Low-dose lung radiotherapy for COVID-19 lung disease a pre-clinical efficacy study in a bleomycin model of pneumonitis

Lowdose Whole-lung Irradiation for COVID-19 Pneumonia: Final Results of a Pilot Study

Dexamethasone in Hospitalized Patients with Covid-19

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label

Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with COVID-19-Related Pneumonia

Low dose radiotherapy in the management of covid19 pneumonia (LOWRAD-Cov19): Preliminary report